The innovative CRO and drug discovery company specialized in neurodegenerative diseases
New model of BBB to assess on the BBB penetrance of molecule on the CNS.
Under healthy condition or pathological conditions (AD, PD or stress conditions).
DON’T HESITATE TO CHALLENGE YOURSELF !
Please click below to get access to this opportunity profile.
- MPP+ induced dopaminergic neuron death through necroptosis and autophagy.
31 Mar 2017, 08:00 - 18:00 - Board # 192
- Amyloid peptide and cytoplasmic TDP-43 accumulation in pathogenesis of ALS : an in vitro study.
01 Apr 2017, 08:00 - 18:00 - Board # 189
Neuro-Sys has developed specific preclinical models of CNS diseases to achieve high-quality efficacy pharmacology as well as mode of action studies, a unique cost-effective strategy to accurately determine the pharmacological profiling of leads compounds and explore their underlying mechanism of action. We provide studies to determine the neuroprotection activity of leads compounds but also of dietary supplements and medical nutrition.
We are dedicated to provide high-level technical expertise and preclinical CRO services in a collaborative relationship with our clients, mainly focusing on :
› Alzheimer’s disease (AD)
› Parkinson’s disease (PD)
› Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease)
› Multiple Sclerosis (MS)
› Peripheral Neuropathies
Neuro-Sys is developing a pipeline of innovative compounds focused on treatments for neurodegenerative diseases, orphan diseases and auto-immune diseases, both internally and through collaborations. We identify our lead compound using our innovative and cutting-edge technology platform, including our proprietary manufacturing process.